Abstract
Biological products are complex mixtures of molecular species. Their individual entities are difficult to characterize. During development and post-approval, improvements are made in production methods, process and control test methods for product characterization, and equipment or facilities. These could result in fundamental changes to the biological product itself, perhaps requiring additional clinical studies to demonstrate that the product’s safety, identity, purity and potency have not been impacted. Consequently, regulations require the sponsor to demonstrate product comparability between the post-change and pre-change products. A stepwise approach to extensively characterize the post-change product and the pre-change product with state-of-the-art technology is the first step in assessing the potential impact on safety and efficacy. These comparability studies should have direct side-by-side comparisons of the pre-change “reference” product and post-change “test” product. In this chapter, statistical methods are reviewed for establishing comparability in relation to critical quality attributes and animal pharmacokinetics (PK) to systematically evaluate the data.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Buonaccorsi J, Demidenko E, Tosteson T (2000) Estimation in longitudinal random effects models with measurement error. Statistica Sinica 10:885–903
Casella G, Berger RL (1990) Statistical inference. Duxbury Press, Belmont, CA
Chatfield MJ, Borman PJ, Damjanov I (2011) Evaluating change during pharmaceutical product development and manufacture-comparability and equivalence. Qual Reliability Eng Int 17: 629–640
Cui H, Ng KW, Zhu L (2004) Estimation in mixed effects model with errors in variables. J Multivar Anal 91:53–73
EMA Committee for Medicinal Products for Human Use (CHMP) (2005) Guideline on similar biological medicinal products. London
Fan J, Zhang JT (2000) Two-step estimation of functional linear models with applications to longitudinal data. J R Stat Soc B 62:303–322
Food and Drug Administration (FDA) of U.S.A. (1996) Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products. Washington, D.C.
Food and Drug Administration (FDA) of U.S.A. (2001) Guidance for industry: statistical approaches to establishing bioequivalence. Washington, D.C.
Food and Drug Administration (FDA) of U.S.A. (2003), Guidance for industry: comparability protocols—chemistry, manufacturing, and controls information. Washington, D.C.
Food and Drug Administration (FDA) of U.S.A. (2005) Guidance for industry: Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. Washington, D.C.
Food and Drug Administration (FDA) of U.S.A. (2012a) Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. Washington, D.C. February 2012
Food and Drug Administration (FDA) of U.S.A. (2012b) Guidance for industry: quality considerations in demonstrating biosimilarity to a reference product. Washington, D.C. February 2012
Food and Drug Administration (FDA) of U.S.A. (2012c) Guidance for industry: biosimilars: questions and answers regarding implementation of the biologics price competition and innovation act of 2009. Washington, D.C. February 2012
Food and Drug Administration (FDA) of U.S.A. (2014) Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Washington, D.C. May 2014
Fuller WA (1987) Measurement error models. Wiley, New York
Genetic Engineering & Biotechnology News (GEN, 2013) Top 20 best-selling drugs of 2012. March 5, 2013. Website: www.genengnews.com/insight-and-intelligence/top-20-best-selling-drugs-of2012/77899775/?page=2
Genetic Engineering & Biotechnology News (GEN, 2014) The top 25 best-selling drugs of 2013. September 16, 2014. Website: http://www.genengnews.com/insight-and-intelligence/the-top-25-best-selling-drugs-of-2013/77900053/
Haidar SH et al (2007) Bioequivalence approaches for highly viable drugs and drug products. Pharm Res 25:237–241
Haidar SH et al (2008) Evaluation of scaling approach for the bioequivalence of highly variable drugs. AAPS J 10:450–454
Hoffman D (2010) One-sided tolerance limits for balanced and unbalanced random effects models. Technometrics 52(3):303–312
Hoffman D, Kringle R (2005) Two-sided tolerance intervals for balanced and unbalanced random effects models. J Biopharm Stat 15:283–293
Howe WG (1969) Two-sided tolerance limits for normal populations – some improvements. J Am Stat Assoc 64:610–620
Hyslop T, Hsuan F, Holder DJ (2000) A small sample confidence interval approach to assess individual bioequivalence. Stat Med 19:2885–2897
ICH guidance (2005): Q5E comparability of biotechnological/biological products subject to changes in their manufacturing process. June 2005
Krishnamoorthy K, Mathew T (2009) Statistical tolerance regions: theory, applications, and computation. Wiley, Hoboken
Krishnamoorthy K, Lian X, Mondal S (2011) Tolerance intervals for the distribution of the difference between two independent normal random variables. Commun Stat Theory Methods 40(1):117–129
Liao JJZ, Darken PF (2013) Comparability of critical quality attributes for establishing biosimilarity. Stat Med 32:462–469
Liao JJZ, Heyse JF (2011) Biosimilarity for follow-on biologics. Stat Biopharm Res 3(3):445–455
Liao JJZ, Schofield TL, Bennett PS (2005) Analyzing highly variable potency data using a linear mixed-effects measurement error model. J Agric Biol Environ Stat 4:388–397
McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. mAbs 3(2):209–217
McCamish M, Woollett G (2013) The continuum of comparability extends to biosimilarity: how much is enough and what clinical data are necessary? Clin Pharmacol Ther 93(4):315–317
Tosteson T, Buonaccorsi J, Demidenko E (1998) Covariate measurement error and the estimation of random effect parameters in a mixed model for longitudinal data. Stat Med 17:1959–1971
Tothfalusi L, Endrenyi L (2003) Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm Res 20:382–389
Weise M et al (2012) Biosimilars: what clinicians should know. Blood 120:5111–5117
World Health Organization (WHO) (2009) Guidelines on evaluation of similar biotherapeutic products (SBPs). World Health Organization, Geneva
Zhong XP, Fung WK, Wei BC (2002) Estimation in linear models with random effects and errors-in-variables. Ann Inst Stat Mat 54(3):595–606
Acknowledgements
The author thanks Drs. Stan Altan, Rick Burdick, Lisa Hendricks and Lanju Zhang for their valuable comments that dramatically improved the presentation of this chapter.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Liao, J.J.Z. (2016). Statistical Methods for Comparability Studies. In: Zhang, L. (eds) Nonclinical Statistics for Pharmaceutical and Biotechnology Industries. Statistics for Biology and Health. Springer, Cham. https://doi.org/10.1007/978-3-319-23558-5_26
Download citation
DOI: https://doi.org/10.1007/978-3-319-23558-5_26
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23557-8
Online ISBN: 978-3-319-23558-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)